Xaria Plus Tablet contains Montelukast 10 mg and Fexofenadine 120 mg, combining the therapeutic effects of a leukotriene receptor antagonist and a second-generation antihistamine. Montelukast selectively blocks leukotriene D4 receptors in the respiratory tract, reducing inflammation, bronchoconstriction, and mucus production, making it effective in the management of asthma and allergic rhinitis. Fexofenadine, a non-sedating antihistamine, competitively inhibits peripheral H1 receptors, alleviating symptoms such as sneezing, nasal congestion, itching, and urticaria associated with allergic conditions. The synergistic action of these two agents provides comprehensive relief from allergic manifestations by targeting multiple pathways involved in the allergic response. Xaria Plus is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management. It is generally well-tolerated, with a low incidence of sedation or adverse effects. Patients should use this medication under medical supervision, especially those with hepatic impairment or a history of hypersensitivity to either component. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential side effects.